Vabicaserin hydrochloride

SKU: orb1308966

Description

Vabicaserin hydrochloride (SCA 136) is a potent and selective 5-HT2C receptor agonist with an EC50 of 8 nM. This compound is a valuable research tool for investigating the 5-HT2C receptor's role in CNS disorders, including obesity and psychiatric conditions, in both in vitro and in vivo experimental models.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 887258-94-8
• MW: 264.79
• Purity: 98.42% (May vary between batches)
• Formula: C₁₅H₂₁ClN₂
• SMILES: Cl.[H][C@@]12CCC[C@]1([H])c1cccc3CNCCN(C2)c13
• Target: 5-HT Receptor
• Solubility: DMSO:55 mg/mL (207.71 mM);H2O:4 mg/mL (15.11 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (7.55 mM)

Bioactivity

• Target IC50:
  5-HT2C:8 nM (EC50)
• In Vivo:
  After administering a single oral dose of [14C]Vabicaserin (50 mg/kg in mice, 5 mg/kg in rats, and 15 mg/kg in dogs), the unchanged drug accounted for less than 19%, 20%, and 35% of the total plasma radioactivity in mice, rats, and dogs, respectively, at all examined time points. The carbamoyl glucuronide (CG) comprised approximately 7-36% of plasma radioactivity in mice, 2-28% in dogs, and was absent in rat plasma following the single [14C]Vabicaserin dose, yet observed in rat plasma after multiple-dose administration of Vabicaserin at higher doses, being roughly 20 times lower than Vabicaserin based on AUC0-24 values at steady state. The plasma AUC0-24 ratios of CG to Vabicaserin were 1.5 in mice and 1.7 in dogs post-single dose. At doses used for safety assessment, these ratios at steady state were lower for mice (0.2-0.6) but slightly higher for dogs (1.8-4.0). CG was detected in dog urine at amounts comparable to the parent drug but was not found in mouse or rat urine post-single dose. Following a 5 mg/kg [14C]Vabicaserin dose in rats, 19-24% of the administered dose was recovered in bile over 24 hours, with CG representing up to 30% of biliary radioactivity. In monkeys, after a single oral 25-mg/kg dose of Vabicaserin, CG plasma concentrations surpassed those of Vabicaserin at all examined postdose intervals (2-24 h), though the CG-to-Vabicaserin ratio declined by 24 h postdose, from 17.5 at 2 h to 1.7 at 24 h, indicating that CG is a major metabolite with a 12:1 AUC0-24 ratio to Vabicaserin.
• In Vitro:
  In Chinese hamster ovary cell membranes, Vabicaserin displaces 125I-(2,5-dimethoxy)phenylisopropylamine binding from human 5-HT2C receptor sites (Ki: 3 nM) and is >50-fold selective over a number of serotonergic, noradrenergic, and dopaminergic receptors. The binding affinity determined for the human 5-HT2B receptor subtype using [3H]5HT is 14 nM. Vabicaserin is a potent and full agonist (EC50, 8 nM; Emax, 100%) in stimulating 5-HT2C receptor-coupled calcium mobilization and exhibits 5-HT2A receptor antagonism and 5-HT2B antagonist or partial agonist activity in transfected cells, depending on the level of receptor expression. Vabicaserin showed a lower affinity at the binding site (22 nM) of 5-HT2C antagonist labeled with [3H]methsulamide. Other binding studies have shown that Vabicaserin has an affinity for 5-HT2B and 5-HT1A receptors with Ki values of 14 and 112 nM, respectively .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, inhibit, 5-hydroxytryptamine Receptor, 5HTReceptor, 5-HT2C, 5-HT2C Receptor, 5-HT Receptor, 5HT Receptor, Serotonin Receptor, SCA 136, SCA136, SCA-136, Vabicaserin, Vabicaserin Hydrochloride, Vabicaserin hydrochloride

Compound Identifiers

PubChem CID

11521821